Publications
Publications
Show Results For
- All HBS Web
(1,287)
- Faculty Publications (514)
- 2000
- Chapter
Measuring Competence? Exploring Firm Effects in Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
- 1996
- Chapter
Eli Lilly and Company: Drug Development Strategy
By: S. Thomke, A. Nimgade and P. Pospisil
- May 2000
- Case
To Trim or Not to Trim: That Is the Question
By: Srikant M. Datar
Should Novartis drop 20% of its global pharmaceutical product brands that account for only 3% of its pharmaceutical revenues? View Details
- February 2000 (Revised October 2000)
- Case
Kendle International Inc.
By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs
Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and... View Details
- December 1999 (Revised August 2001)
- Case
Millennium Pharmaceuticals, Inc. (A)
By: Stefan H. Thomke and Ashok Nimgade
Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details
- December 1999
- Case
Agrochemicals at Ciba-Geigy AG (A)
By: Michael L. Tushman, Wendy Smith and Daniel Radov
After spending five years to develop a revolutionary product, the director of Ciba-Geigy's fungicide research department is handed an unfavorable market study. The case details the R&D process for the new product, including information on corporate partnerships,... View Details
Keywords: Agribusiness; Plant-Based Agribusiness; Research and Development; Innovation and Invention; Innovation Strategy; Product Launch; Marketing Channels; Change Management; Product Development; Business Processes; Organizational Structure; Corporate Accountability; Pharmaceutical Industry; Pharmaceutical Industry
- December 1999 (Revised January 2000)
- Case
Agrochemicals at Ciba-Geigy AG (B)
By: Michael L. Tushman, Wendy Smith and Daniel Radov
Focuses on Pierre Urech's efforts to change the division structure at Ciba-Geigy to facilitate the marketing of the new product. Details the relationships Urech cultivates and the strategy he pursues as "product champion." Also describes the restructuring of the... View Details
- December 1999 (Revised February 2001)
- Case
CVS: The Web Strategy
By: John A. Deighton and Anjali C. Shah
How should America's second-largest pharmacy chain respond to the challenge from online drugstores? What threat does the web pose to bricks and mortar distribution of prescription drugs and the other items that make up 50% of a drugstore's sales? This case describes... View Details
- November 1999
- Teaching Note
drugstore.com TN
By: Richard L. Nolan
Teaching Note for (9-300-036). View Details
- November 1999
- Supplement
"ACT UP": Peter Staley, An Interview with Professor Willis Emmons, November 17, 1995
Provides excerpts from an interview with Peter Staley of Act Up reflecting on the Wall Street protest against Burroughs Wellcome in the fall of 1989 and on the role and impact of AIDS advocacy and activism in general. View Details
- 1999
- Chapter
The Pharmaceutical Industry and the Revolution in Molecular Biology: Interactions Among Scientific, Institutional, and Organizational Change
By: Rebecca Henderson, Gary P. Pisano and Luigi Orsenigo
- September 1999
- Teaching Note
Eli Lilly: The Evista Project TN
Teaching Note for (9-699-016). View Details
Keywords: Pharmaceutical Industry
- July 1999
- Supplement
Jan Eriksson of Novartis Indonesia
By: Christopher A. Bartlett and Carin-Isabel Knoop
A follow-up interview, in Summer 1998, with the protagonist of the Novartis Indonesia case series. He describes ongoing strategy and activities. View Details
- June 1999 (Revised October 1999)
- Case
Eli Lilly, 1998 (A): Strategic Challenges
By: Michael Y. Yoshino and Thomas W. Malnight
Deals with key strategic challenges facing Eli Lilly, a highly successful U.S.-based drug company. View Details
- June 1999 (Revised October 1999)
- Case
Eli Lilly, 1998 (B): Emerging Global Organization
By: Michael Y. Yoshino and Thomas W. Malnight
Examines major issues faced by Eli Lilly as it evaluates the appropriateness of a focused matrix organization with extensive use of cross-functional teams. View Details
- June 1999 (Revised June 2000)
- Case
Eckerd Corporation
By: Michael E. Porter and John E. Kelleher
Describes the history and current situation in the retail pharmacy industry, including competition from new merchants and Internet drugstores. Eckerd, one of the top four drug chains, must decide how to position itself for the future. View Details